Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CPRXNYSE:MYOVNASDAQ:NXTCNASDAQ:TXMDOTCMKTS:VEGPF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$15.13-1.4%$15.41$11.09▼$17.76$1.79B0.891.50 million shs7.42 million shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsNXTCNextCure$1.60+1.9%$1.73$0.98▼$2.57$44.64M0.4238,825 shs61,697 shsTXMDTherapeuticsMD$1.86-1.6%$2.26$1.86▼$4.73$21.45M1.0321,382 shs10,322 shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/A13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.37%-0.59%-10.53%+3.91%-12.69%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%NXTCNextCure+1.91%-16.67%+13.48%+41.59%+3.23%TXMDTherapeuticsMD-2.11%-6.53%-20.85%-16.63%-49.59%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.9869 of 5 stars4.51.00.03.92.93.34.4MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure3.9946 of 5 stars3.53.00.04.60.61.71.3TXMDTherapeuticsMDN/AN/AN/AN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals3.00Buy$26.4374.68% UpsideMYOVMyovant SciencesN/AN/AN/AN/ANXTCNextCure3.00Buy$6.00275.00% UpsideTXMDTherapeuticsMD2.00HoldN/AN/AVEGPFVectura GroupN/AN/AN/AN/ACurrent Analyst RatingsLatest TXMD, NXTC, MYOV, VEGPF, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024CPRXCatalyst PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$29.003/22/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/14/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.003/7/2024CPRXCatalyst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/1/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $34.003/1/2024CPRXCatalyst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$398.20M4.48$1.94 per share7.78$3.30 per share4.58MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ATXMDTherapeuticsMD$1.30M16.50N/AN/A$2.77 per share0.67VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$0.6124.806.940.8817.93%26.56%22.13%5/8/2024 (Estimated)MYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ANXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)TXMDTherapeuticsMD-$10.28MN/A0.00∞N/AN/A-25.54%-14.87%5/20/2024 (Estimated)VEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/ALatest TXMD, NXTC, MYOV, VEGPF, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A2/28/2024Q4 2023CPRXCatalyst Pharmaceuticals$0.45$0.49+$0.04$0.67$105.78 million$110.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A2.882.68MYOVMyovant SciencesN/A1.571.45NXTCNextCureN/A16.3816.38TXMDTherapeuticsMDN/A1.721.72VEGPFVectura GroupN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%MYOVMyovant Sciences30.62%NXTCNextCure42.65%TXMDTherapeuticsMD30.74%VEGPFVectura GroupN/AInsider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals12.10%MYOVMyovant Sciences1.90%NXTCNextCure11.90%TXMDTherapeuticsMD1.20%VEGPFVectura GroupN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals167118.01 million103.73 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableNXTCNextCure8227.90 million24.58 millionOptionableTXMDTherapeuticsMD111.53 million11.39 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableTXMD, NXTC, MYOV, VEGPF, and CPRX HeadlinesSourceHeadlineCritical Review: Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF)americanbankingnews.com - April 20 at 1:26 AMEuropean Stocks See Mixed Session as U.K.'s FTSE Leadsthestreet.com - January 16 at 11:20 PMVECTURA GROUP LS -,000271 (V4TA.BE)finance.yahoo.com - January 15 at 2:59 PMVectura Group PLC (V4TA.BE)finance.yahoo.com - January 9 at 10:12 AMResults for 'Vectura-Fertin Pharma'afaqs.com - October 11 at 7:33 PMVectura Group (OTC:VEGPF), Short Interest Reportbenzinga.com - July 18 at 11:14 PMCarlyle stays in race for Vecturauk.finance.yahoo.com - August 27 at 12:54 PMForm 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826finance.yahoo.com - August 27 at 6:38 AMPhilip Morris chief attacks critics as Vectura bid tests investorsuk.finance.yahoo.com - August 20 at 2:24 AMMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closeruk.finance.yahoo.com - August 13 at 4:18 AMVectura auction called off after Carlyle declines to beat Philip Morris biduk.finance.yahoo.com - August 10 at 3:02 PMUPDATE 1-Vectura takeover battle could slip into auction - UK regulatorfinance.yahoo.com - August 9 at 8:04 AMPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ringca.finance.yahoo.com - August 9 at 8:04 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCatalyst PharmaceuticalsNASDAQ:CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Myovant SciencesNYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.TherapeuticsMDNASDAQ:TXMDTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Vectura GroupOTCMKTS:VEGPFVectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.